Send me real-time posts from this site at my email
Motley Fool

Why MacroGenics Stock Jumped Today

What happened

Shares of MacroGenics (NASDAQ: MGNX) had jumped 5.3% as of 3:09 p.m. EST on Monday. The gain came after the company announced results from a late-stage study of Margenza as a third-line treatment for metastatic HER2-positive breast cancer. These results were published in the Journal of the American Medical Association Oncology.

So what

MacroGenics stated that Margenza met the primary endpoint of the phase 3 study with a 24% progression-free survival relative risk reduction versus Roche's Herceptin. Both Margenza and Herceptin were administered along with chemotherapy.

Image source: Getty Images.

Investors reacted positively to the latest results, which bode well for Margenza's prospects in achieving commercial success. The drug won Food and Drug Administration approval as a third-line treatment for HER2-positive breast cancer in December.

CEO Scott Koenig said that Margenza is "the first HER2-targeted therapy to reduce the risk of disease progression in metastatic breast cancer patients over trastuzumab [Herceptin] in a head-to-head comparison involving a heavily pre-treated patient population." The potential market opportunity for Margenza should be significant. As many as 20% of breast cancers diagnosed are HER2-positive. Herceptin has long been a leading treatment for HER2-positive breast cancer. An even better therapy would be welcomed by physicians and patients.

Now what

What's the next likely catalyst for the biotech stock? MacroGenics expects to launch Margenza in the U.S. beginning in March. The company's first-quarter update could provide a hint as to how the rollout is going, but its second-quarter update will likely give a better picture.

10 stocks we like better than MacroGenics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and MacroGenics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of November 20, 2020

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue